Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 9/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14305454 | 0.89 | CYP11B1 (0.54) | CYP11B1CYP11B2KMT2A | |
| SCHEMBL7138890 | 0.81 | CYP11B1 (0.57) | CYP11B1CYP11B2KMT2ATDP1L3MBTL1 | |
| SCHEMBL1762390 | 0.81 | CYP11B1 (0.57) | CYP11B1CYP11B2KMT2ATDP1L3MBTL1 | |
| SCHEMBL7134349 | 0.81 | CYP11B1 (0.66) | CYP11B1CYP11B2KMT2ATDP1L3MBTL1 | |
| SCHEMBL6907021 | 0.80 | CYP11B2 (0.65) | CYP11B1CYP11B2KMT2ATDP1CYP19A1 | |
| SCHEMBL6906443 | 0.80 | CYP11B1 (0.60) | CYP11B1CYP11B2KMT2ATDP1L3MBTL1 | |
| SCHEMBL7138423 | 0.80 | CYP11B1 (0.66) | CYP11B1CYP11B2KMT2ATDP1L3MBTL1 | |
| SCHEMBL1762394 | 0.79 | CYP11B1 (0.56) | CYP11B1CYP11B2KMT2ATDP1L3MBTL1 | |
| SCHEMBL11717588 | 0.78 | NPC1 (0.57) | KMT2A | |
| SCHEMBL6907674 | 0.78 | CYP11B1 (0.58) | CYP11B1CYP11B2KMT2ATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541404-B2 | Inhibitors of the human aldosterone synthase CYP11B2 | ELEXOPHARM GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20110118241-A1 | 6-Pyridin-3-YL-3,4-Dihydro-1H-Quinolin-2-One Derivatives and Related Compounds as Inhibitors of the Human Aldosterone Synthase CYP11B2 | UNIVERSITAT DES SAARLANDES (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110112067-A1 | Inhibitors of the Human Aldosterone Sythase CYP11B2 | UNIVERSITAT DES SAARLANDES (DE) | 2011-05-12 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| EP-1891954-A2 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2008-02-27 | — | — | EP | disclosed |
| EP-0807631-B1 | Tricyclic compounds having fungicidal activity, their preparation and their use | SANKYO CO (JP) | 2003-03-12 | — | — | EP | disclosed |
| US-5981752-A | Tricyclic compounds having fungicidal activity, their preparation and their use | SANKYO COMPANY, LIMITED (JP) | 1999-11-09 | — | — | US | disclosed |
| US-5773618-A | PYRROLOQUINOLINONE DERIVATIVES | SANKYO COMPANY, LIMITED (JP) | 1998-06-30 | — | — | US | disclosed |
| EP-0807631-A1 | Tricyclic compounds having fungicidal activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | CYP11B1 2330/4885CYP11B2 2317/4885KMT2A 1919/4885 |
| US-20110118241-A1 | 6-Pyridin-3-YL-3,4-Dihydro-1H-Quinolin-2-One Derivatives and Related Compounds as Inhibitors of the Human Aldosterone Synthase CYP11B2 | HSD11B1, HSD11B2, CYP4A11 | CYP11B1 6/4885CYP11B2 4/4885KMT2A 2403/4885 |
| US-20110112067-A1 | Inhibitors of the Human Aldosterone Sythase CYP11B2 | HSD11B1, HSD11B2, CYP11B1 | CYP11B1 3/4885CYP11B2 4/4885KMT2A 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.